Heron Therapeutics (HRTX) Q4 Earnings: Taking a Look at Key Metrics Versus Estimates

Core Insights - Heron Therapeutics reported revenue of $40.78 million for Q4 2024, marking a year-over-year increase of 19.1% and exceeding the Zacks Consensus Estimate of $36.95 million by 10.37% [1] - The company achieved an EPS of $0.02, a significant improvement from -$0.07 a year ago, resulting in an EPS surprise of 166.67% compared to the consensus estimate of -$0.03 [1] Financial Performance - Net Product Sales for the Oncology Care Franchise (Sustol) were $3.52 million, slightly above the estimated $3.38 million, but a decrease of 7.4% year-over-year [4] - Net Product Sales for the Acute Care Franchise (Aponvie) reached $1.93 million, significantly surpassing the estimated $1.43 million, reflecting a year-over-year increase of 311.1% [4] - Net Product Sales for the Acute Care Franchise (Zynrelef) totaled $8.46 million, exceeding the average estimate of $6.88 million, with a year-over-year growth of 48.5% [4] - Net Product Sales for the Oncology Care Franchise (Cinvanti) amounted to $26.87 million, above the estimated $25.40 million, representing a year-over-year increase of 10.7% [4] Market Performance - Shares of Heron Therapeutics have returned +2.4% over the past month, contrasting with the Zacks S&P 500 composite's decline of -2.2% [3] - The stock currently holds a Zacks Rank 3 (Hold), indicating potential performance in line with the broader market in the near term [3]